| Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. | |
| | |
MedLine Citation:
|
PMID: 20228679 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To determine the acute effects of exogenous glucagon-like peptide-1 on gastric emptying, glucose absorption, glycemia, plasma insulin, and glucagon in critically ill patients. DESIGN: Randomized, double-blind, crossover study. SETTING: Intensive care unit. SUBJECTS: Twenty-five mechanically ventilated patients, without known diabetes, studied on consecutive days. INTERVENTIONS: Intravenous glucagon-like peptide-1 (1.2 pmol/kg/min) or placebo was infused between -30 and 330 mins. At 0 min, 100 mL liquid nutrient (1 kcal/mL) including 100 microg of 13C-octanoic acid and 3 grams of 3-O-methyl-glucose was administered. MEASUREMENTS AND MAIN RESULTS: Blood glucose, serum 3-O-methyl-glucose (as an index of glucose absorption), insulin and glucagon concentrations, as well as exhaled 13CO2 were measured. The gastric emptying coefficient was calculated to quantify gastric emptying. Data are presented as mean (sd). There was a nonsignificant trend for glucagon-like peptide-1 to slow gastric emptying (gastric emptying coefficient) (glucagon-like peptide-1, 2.45 [0.93] vs. placebo, 2.75 [0.83]; p = .09). In 11 of the 25 patients, gastric emptying was delayed during placebo infusion and glucagon-like peptide-1 had no detectable effect on gastric emptying in this group (1.92 [0.82] vs. 1.90 [0.68]; p = .96). In contrast, in patients who had normal gastric emptying during placebo, glucagon-like peptide-1 slowed gastric emptying substantially (2.86 [0.58] vs. 3.41 [0.37]; p = .006). Glucagon-like peptide-1 markedly reduced the rate of glucose absorption (3-O-methyl-glucose area under the curve(0-330), 37 [35] vs. 76 [51] mmol/L/min; p < .001), decreased preprandial glucagon (at 0 min change in glucagon, -15 [15] vs. -3 [14] pmol/L; p < .001), increased the insulin/glucose ratio throughout the infusion (area under the curve(-30-330), 1374 [814] vs. 1172 [649] mU/mmol/min; p = .041), and attenuated the glycemic response to the meal (glucose area under the curve(0-330), 2071 [353] vs. 2419 [594] mmol/L/min; p = .001). CONCLUSIONS: Exogenous glucagon-like peptide-1 lowers postprandial glycemia in the critically ill. This may occur, at least in part, by slowing gastric emptying when the latter is normal but not when it is delayed. |
| | |
Authors:
|
Adam M Deane; Marianne J Chapman; Robert J L Fraser; Matthew J Summers; Antony V Zaknic; James P Storey; Karen L Jones; Christopher K Rayner; Michael Horowitz |
Related Documents
:
|
17683169 - Pathophysiology and management of diabetic gastropathy: a guide for endocrinologists. 18322959 - Gastric motor effects of ghrelin and growth hormone releasing peptide 6 in diabetic mic... 17617279 - Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus. 3721699 - Gastric emptying after gastric bypass. 10511299 - Measurement of gastric emptying by standardized real-time ultrasonography in healthy su... 16843939 - The effect of intravenous lipids on gastric emptying in rats subjected to total parente... 19811109 - Examining and interpreting responsiveness of the diabetes medication satisfaction measure. 2866759 - Photocoagulation for diabetic macular edema. early treatment diabetic retinopathy study... 1797439 - Correlation between glycated lipoproteins and fructosamine level in serum. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Critical care medicine Volume: 38 ISSN: 1530-0293 ISO Abbreviation: Crit. Care Med. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-04-21 Completed Date: 2010-05-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0355501 Medline TA: Crit Care Med Country: United States |
Other Details:
|
Languages: eng Pagination: 1261-9 Citation Subset: AIM; IM |
Affiliation:
|
Intensive Care Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia. Adam.Deane@adelaide.edu.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
3-O-Methylglucose
/
blood Blood Glucose / analysis Breath Tests Critical Illness* Cross-Over Studies Double-Blind Method Gastric Emptying / drug effects Glucagon / blood Glucagon-Like Peptide 1 / pharmacology* Glucose / metabolism* Humans Insulin / blood Intensive Care Units Respiration, Artificial |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 11061-68-0/Insulin; 146-72-5/3-O-Methylglucose; 50-99-7/Glucose; 89750-14-1/Glucagon-Like Peptide 1; 9007-92-5/Glucagon |
| Comments/Corrections | |
Comment In:
|
Crit Care Med. 2010 May;38(5):1379-80
[PMID:
20404632
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The effect of a family support intervention on family satisfaction, length-of-stay, and cost of care...
Next Document: Toll-like receptor 2 plays a critical role in cardiac dysfunction during polymicrobial sepsis.